Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
August 31, 2023
Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer
Article links to www.globenewswire.com
September 27, 2023
Sitryx raises additional $39 million to progress development of disease-modifying therapeutics
Article links to prn.to
October 3, 2023
The Oxford-Harrington Rare Disease Centre Launches
Article links to www.beacontx.com
June 12, 2023
Beacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases
Article links to innovation.ox.ac.uk
May 22, 2023
Oxford University retains No. 1 spot for spinouts
Article links to www.ultromics.com
April 26, 2023
Ultromics granted FDA Breakthrough Device Designation
Article links to www.caristo.com
April 17, 2023
Caristo Diagnostics Completes Series A Financing and Welcomes New CEO
Article links to quantummotion.tech
February 21, 2023
Quantum Motion Raises £42 Million Investment Round
All News
13•11•23
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer
06•09•23
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the Board
18•10•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
13•06•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Dina Anderson as Vice President of Operations
20•04•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer
15•02•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer
11•02•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces formation of advisory board
05•11•21
Portfolio News
Nucleome Therapeutics
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
24•05•21
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
24•05•21
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal